⚠ Evidence warning: Clinical trials or other evidence do not support the claims that low-dose naltrexone helps postural orthostatic tachycardia syndrome and the listed best-responder groups. This page keeps it as a report of what people, websites or other media say.

Low-Dose Naltrexone for Postural Orthostatic Tachycardia Syndrome (POTS)

Low Dose Naltrexone for postural orthostatic tachycardia syndrome — scientific infographic poster

Table of Contents

  1. What Low Dose Naltrexone Actually Is
  2. Why It Helps Postural Orthostatic Tachycardia Syndrome
  3. What the Evidence Shows
  4. Who Low Dose Naltrexone Is Best For
  5. Who the Research Raises Concerns For
  6. Starting Protocol — Titration
  7. Side Effects and How to Manage Them
  8. Where Low Dose Naltrexone Comes From — Compounding Pharmacies
  9. How Patients Obtain a Prescription When the Doctor Is Not Familiar With It
  10. Combining Low Dose Naltrexone with Other Postural Orthostatic Tachycardia Syndrome Treatments
  11. Timeline of Expected Effects
  12. What “Worked” Looks Like
  13. Key Research Papers
  14. Connections
  15. Featured Videos

1. What Low Dose Naltrexone Actually Is

Naltrexone is a pure opioid receptor antagonist. At its U.S. Food and Drug Administration-approved dose of 50 mg daily, it’s used to treat opioid dependence and alcohol use disorder — it blocks the mu-opioid receptor continuously so that opioids and alcohol-driven endorphin reward produce no high.

At low doses (1.5–4.5 mg), the drug behaves almost nothing like its 50 mg self. Two completely different mechanisms take over:

The opioid-receptor blockade itself does nothing therapeutic — it’s the rebound and the microglial effects that matter. That is why low dose naltrexone (LDN) doesn’t feel like anything when you take it; it isn’t working through an acute pharmacologic effect the way a beta-blocker does.

Back to Table of Contents

2. Why It Helps Postural Orthostatic Tachycardia Syndrome

Two strands of postural orthostatic tachycardia syndrome (POTS) research point directly at what low dose naltrexone does.

Autoimmunity. Roughly 25–50% of postural orthostatic tachycardia syndrome patients in screened cohorts carry functional autoantibodies against adrenergic and muscarinic receptors — most notably the AT1R (angiotensin II type 1 receptor), alpha-1 adrenergic receptor, and beta-1 and beta-2 adrenergic receptors. These antibodies act as partial agonists or antagonists and appear to drive at least a subset of the orthostatic dysregulation.

Neuroinflammation. Post-viral postural orthostatic tachycardia syndrome (post-EBV, post-influenza, post-Lyme, long COVID) shows features consistent with chronic low-grade neuroinflammation — persistent fatigue, brain fog, post-exertional malaise, sensitivity to light and sound. Microglia in a sustained M1-polarized state amplify autonomic dysregulation in the brainstem nuclei that govern heart rate and vascular tone.

Low dose naltrexone’s microglial TLR4 effect is a plausible brake on that inflammatory loop, and its endorphin-rebound effect modulates pain processing and autonomic balance. Case series and patient-reported outcomes describe improvements in fatigue, brain fog, orthostatic symptoms, pain, and mast cell overlap symptoms.

Back to Table of Contents

3. What the Evidence Shows

Honest summary: there are no large randomized controlled trials of low dose naltrexone for postural orthostatic tachycardia syndrome specifically. The evidence base is pieced together from three sources.

Low dose naltrexone is not a miracle drug for postural orthostatic tachycardia syndrome. Practitioners who prescribe it describe modest-to-moderate improvement, most useful when stacked with other postural orthostatic tachycardia syndrome treatments rather than used as a standalone therapy.

Back to Table of Contents

4. Who Low Dose Naltrexone Is Best For

Response is not uniform. Practitioners describe these subgroups as the most likely to benefit:

Back to Table of Contents

5. Who the Research Raises Concerns For

Back to Table of Contents

6. Starting Protocol — Titration

The classic target dose is 4.5 mg at bedtime, which practitioners describe reaching by slow titration. Starting at the target dose is the most common reason patients bounce off low dose naltrexone with vivid dreams or a symptom flare.

A meaningful minority of patients feel best on 2–3 mg and worse at 4.5 mg. Practitioners describe adjusting the dose by symptom response rather than by reaching the maximum dose, and moving to morning dosing when vivid dreams or insomnia persist — many patients report tolerating it equally well and some prefer it.

Back to Table of Contents

7. Side Effects and How to Manage Them

Back to Table of Contents

8. Where Low Dose Naltrexone Comes From — Compounding Pharmacies

Low dose naltrexone is not a stock pharmacy item at these doses. Commercial naltrexone comes as 50 mg tablets; trying to split a tablet into 1/30th is unreliable and potentially unsafe. It is made by compounding pharmacies, which prepare low dose naltrexone capsules or liquid in the exact dose prescribed (0.5, 1, 1.5, 2, 3, 4.5 mg are standard).

Many compounding pharmacies across the US prepare low dose naltrexone.

Cost: typically $35–75 per month cash pay. Some insurers will cover with prior authorization, especially when the prescribing indication is fibromyalgia, Crohn’s, or another off-label use. Any MD, DO, NP, or PA can write the prescription — no specialty licensure required.

Back to Table of Contents

9. How Patients Obtain a Prescription When the Doctor Is Not Familiar With It

Most primary care physicians have never prescribed low dose naltrexone, and patients describe arriving prepared.

An initial visit plus a compounding script is usually all it takes. Refills are straightforward once the pharmacy relationship is set up.

Back to Table of Contents

10. Combining Low Dose Naltrexone with Other Postural Orthostatic Tachycardia Syndrome Treatments

Low dose naltrexone plays well with essentially every standard postural orthostatic tachycardia syndrome medication:

The one real-world constraint is opioids — any scheduled opioid analgesic, including tramadol, is incompatible while low dose naltrexone is onboard. For stacking strategy with other postural orthostatic tachycardia syndrome drugs, see the Medications Guide.

Back to Table of Contents

11. Timeline of Expected Effects

Low dose naltrexone is slow. Practitioners report that most patients notice the first meaningful shift at 4–8 weeks at target dose. A minority of responders feel it within 1–2 weeks, usually as improved energy or reduced brain fog first.

Practitioners describe a fair trial as at least 3 months at target dose before a person is judged a non-responder, and describe people who feel well at 3 mg staying at that dose — target dose is not the same as optimal dose.

Back to Table of Contents

12. What “Worked” Looks Like

Responders typically describe:

The effect is often subtle at first. Practitioners describe a weekly symptom diary — standing heart rate, fatigue score, brain fog score, flare count — as the most reliable way to see whether low dose naltrexone is helping.

Back to Table of Contents

Key Research Papers

  1. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical Rheumatology. 2014;33(4):451–459. — doi:10.1007/s10067-014-2517-2
  2. Toljan K, Vrooman B. Low-Dose Naltrexone (LDN) — Review of Therapeutic Utilization. Medical Sciences (Basel). 2018;6(4):82. — doi:10.3390/medsci6040082
  3. Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis & Rheumatism. 2013;65(2):529–538. — PubMed PMID: 23359310
  4. Weinstock LB, Brook JB, Myers TL, Goodman B. Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment. BMJ Case Rep. 2018;2018:bcr-2017-221405. — doi:10.1136/bcr-2017-221405
  5. Stallkamp Tidd SJ, Cantrell C, Greene BD, Wilson R. Low-Dose Naltrexone Use in Postural Orthostatic Tachycardia Syndrome: A Case Series. Cureus. 2023;15(8):e43426. — PubMed PMID: 37706146
  6. Zapata N, Georgiadi E, Cantrell C, Rilinger RG, Levine MA, Wilson R. Low-Dose Naltrexone for Managing Pain and Autonomic Symptoms in Patients With Dysautonomia. Cureus. 2025;17(6):e86538. — PubMed PMID: 40698237
  7. Rodríguez-Freire C, Navarrete J, Rozadilla-Sacanell A, Sanabria-Mazo JP, Del Pino-Gaya B, Borràs X, Feliu-Soler A, Luciano JV. Efficacy of Low-Dose Naltrexone in Women With Fibromyalgia Syndrome: A 12-Month Randomised, Double-Blind, Placebo-Controlled Single-Centre Clinical Trial (INNOVA Study). European Journal of Pain. 2026;30(6):e70321. — PubMed PMID: 42385209
  8. Bruun KD, Nielsen MJ, Vaegter HB, Blichfeldt-Eckhardt MR, Amris K, Pedersen JR. Low-dose naltrexone for fibromyalgia: a re-analysis suggests lower efficacy than previously reported. Korean Journal of Pain. 2026;39(1):140–143. — PubMed PMID: 41469218
  9. Chopra P, Cooper MS. Treatment of Complex Regional Pain Syndrome (CRPS) using low dose naltrexone (LDN). Journal of Neuroimmune Pharmacology. 2013;8(3):470–476. — PubMed PMID: 23546884
  10. Byambasuren O, Atkins T, Baptista S, Glasziou P, Chakraborty S. Effect of low-dose naltrexone for long COVID: a systematic review and meta-analysis. BMJ Open. 2026;16(7):e111253. — PubMed PMID: 42463201

PubMed Topic Searches

Curated PubMed topic searches — each link opens a live query so you always see the most recent literature.

  1. PubMed: Low-dose naltrexone for POTS
  2. PubMed: LDN for fibromyalgia
  3. PubMed: LDN and autoimmune disease
  4. PubMed: Naltrexone, microglia, and TLR4
  5. PubMed: LDN for long COVID
  6. PubMed: Naltrexone and mast cells
  7. PubMed: LDN for chronic fatigue syndrome

Back to Table of Contents

Connections

Back to Table of Contents